South Korea Gene Therapy Market Trends, Share, Size, Demand, Revenue and Future Outlook
South Korea Gene Therapy Market Growth, Size, Trends Analysis- By Vector Type, By Method, By Gene Type, By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Dec-2024 | Report ID: HLCA2497 | Pages: 1 - 109 | Formats*: |
| Category : Healthcare | |||
South Korea Gene Therapy Market Introduction and Overview
According to SPER Market Research, the South Korea Gene Therapy Market is estimated to reach USD 15.33 million by 2033 with a CAGR 16.89%.
The report includes an in-depth analysis of the South Korea Gene Therapy Market, including market size and trends, product mix, distribution channels, and supplier analysis. Gene therapy is a medical procedure that involves changing, deleting, or adding particular genes to a patient's cells in order to address genetic problems. Targeting the underlying genetic cause, this therapeutic approach has the potential to treat hereditary disorders like cancer or cystic fibrosis. It has demonstrated positive outcomes in clinical trials and holds potential for personalized therapy.
- The Swiss Agency for Therapeutic Products approved Libmeldy in December 2023 to treat early-onset metachromatic leukodystrophy, which was a major step toward meeting the therapeutic demands of this uncommon condition.
Market Opportunities and Challenges
Opportunities: The country's increased frequency of genetic and chronic diseases and disorders, government activities, approvals, and major technological developments in genomic medicines all contribute to the market's growth. Gene therapy is a revolutionary method of treating illnesses by altering genetic material to replace or fix damaged genes. Increased investment in research and development, the incidence of chronic diseases and genetic abnormalities, and scientific breakthroughs have all contributed to the considerable uptake of this novel therapeutic approach in South Korea. Furthermore, Products involving gene therapy must pass stringent regulatory review before being approved. They produce longer-lasting and more powerful therapeutic effects than conventional medications by acting at the genetic level. This significant benefit that gene therapy products provide has been seen to contribute to an increase in the number of approvals that these treatments have gotten. Between 2021 and 2023, over ten products were authorized by the US FDA. Additionally, a sizable number of clinically developed medications are anticipated to obtain final approval throughout the projection period. Thus, during the projection period, this is a key element propelling the market's expansion.
Challenges: A lot of research and development is being done to provide cutting-edge treatments like gene therapy. As a result, they require a substantial time and financial commitment. Clinical trials, preclinical testing, laboratory research, and regulatory approval are all included in the expenses. Additionally, vectors used in gene therapy products must be created and individually developed according to specifications. The entire production process becomes more complex as a result. Production expenses are raised by the need for strict adherence to quality standards and carefully controlled manufacturing processes. Additionally, gene therapies are not mass-produced and are highly focused treatments. All of these elements contribute to the high price of gene therapy products, which hinders their uptake, particularly in underdeveloped nations.
Market Competitive Landscape
The Gene Therapy market is moderately fragmented in South Korea. Some of the market players are CHA Biotech Co., Ltd., CORESTEMCHEMON Inc., Ferring International Center S.A., HELIXMITH Co., Ltd., MEDIPOST Co., Ltd., Novartis Korea Ltd., PHARMICELL Co., Ltd., Rznomics Inc., S-Biomedic, Tego Science, Inc.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Vector Type, By Method, By Gene Type, By Application, By End User |
| Regions covered | Eastern, Western, Northern, Southern |
| Companies Covered | CHA Biotech Co., Ltd., CORESTEMCHEMON Inc., Ferring International Center S.A., HELIXMITH Co., Ltd., MEDIPOST Co., Ltd., Novartis Korea Ltd., PHARMICELL Co., Ltd., Rznomics Inc., S-Biomedic, Tego Science, Inc. |
COVID-19 Impact on South Korea Gene Therapy Market
The South Korean gene therapy market was significantly impacted by the COVID-19 pandemic, which caused disruptions in a number of different domains. Clinical trials were halted, research facilities were restricted, and research and development (R&D) efforts were significantly delayed. As a result, ongoing research was slowed down, patient recruitment was restricted, and advancements in gene therapy were impeded. The supply chain for gene therapy goods was also impacted, as lockdowns and travel restrictions caused production difficulties and raw material shortages. Due to economic uncertainties that made investors more cautious and the fact that government and private sector resources were frequently diverted to COVID-19 response efforts, the pandemic resulted in a decrease in financial investments in the sector.
Key Target Audience:
- Individual Pharmaceutical and Biotech Companies
- Healthcare Providers and Hospitals
- Regulatory Authorities
- Researchers and Academics
- Gene Therapy Manufacturers
- Investors and Venture Capitalists
- Patients and Patient Advocacy Groups
- Government and Public Health Agencies
Our in-depth analysis of the South Korea Gene Therapy Market includes the following segments:
| By Vector Type: | |
| By Method: | |
| By Gene Type: | |
| By Application: | |
| By End User: |
Key Topics Covered in the Report:
- South Korea Gene Therapy Market Size (FY’2024-FY’2033)
- Overview of South Korea Gene Therapy Market
- Segmentation of South Korea Gene Therapy Market By Vector Type (Viral Vector, Non-Viral Vector)
- Segmentation of South Korea Gene Therapy Market By Method (Ex-Vivo, In-Vivo)
- Segmentation of South Korea Gene Therapy Market By Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth factors, Receptors, Others)
- Segmentation of South Korea Gene Therapy Market By Application (Ocological Disorders, Cardiovascular Diseases, Infectious Diseases, Rare Diseases, Neurological Disorders, Other Diseases)
- Expansion Analysis of South Korea Gene Therapy Market
- Problems and Obstacles in South Korea Gene Therapy Market
- Competitive Landscape in the South Korea Gene Therapy Market
- Impact of COVID-19 and Demonetization on South Korea Gene Therapy Market
- Details on Current Investment in South Korea Gene Therapy Market
- Competitive Analysis of South Korea Gene Therapy Market
- Prominent Players in the South Korea Gene Therapy Market
- SWOT Analysis of South Korea Gene Therapy Market
- South Korea Gene Therapy Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the South Korea Gene Therapy Market
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. South Korea Gene Therapy Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in South Korea Gene Therapy Market
7. South Korea Gene Therapy Market, By Vector Type (USD Million) 2020-2033
7.1. South Korea Gene Therapy Market Size, Share and Forecast, By Vector Type, 2020-20267.2. South Korea Gene Therapy Market Size, Share and Forecast, By Vector Type, 2027-20337.3. Viral Vector7.4. Non-Viral Vector
8. South Korea Gene Therapy Market, By Method (USD Million) 2020-2033
8.1. South Korea Gene Therapy Market Size, Share and Forecast, By Method, 2020-20268.2. South Korea Gene Therapy Market Size, Share and Forecast, By Method, 2027-20338.3. Insurance Agents/ Brokers8.4. Ex-Vivo8.5. In-Vivo
9. South Korea Gene Therapy Market, By Gene Type (USD Million) 2020-2033
9.1. South Korea Gene Therapy Market Size, Share and Forecast, By Gene Type, 2020-20269.2. South Korea Gene Therapy Market Size, Share and Forecast, By Gene Type, 2027-20339.3. Antigen9.4. Cytokine9.5. Tumor Suppressor9.6. Suicide9.7. Deficiency9.8. Growth factors9.9. Receptors9.10. Others
10. South Korea Gene Therapy Market, By Application (USD Million) 2020-2033
10.1. South Korea Gene Therapy Market Size, Share and Forecast, By Application, 2020-202610.2. South Korea Gene Therapy Market Size, Share and Forecast, By Application, 2027-203310.3. Oncological Disorders10.4. Cardiovascular Diseases10.5. Infectious Diseases10.6. Rare Diseases10.7. Neurological Disorders10.8. Other Diseases
11. South Korea Gene Therapy Market, By End User (USD Million) 2020-2033
11.1. South Korea Gene Therapy Market Size, Share and Forecast, By End User, 2020-202611.2. South Korea Gene Therapy Market Size, Share and Forecast, By End User, 2027-203311.3. Cancer Institutes11.4. Hospitals11.5. Research institutes11.6. Others
12. South Korea Gene Therapy Market Forecast, 2020-2033 (USD Million)
12.1. South Korea Gene Therapy Market Size and Market Share
13. South Korea Gene Therapy Market, By Region, 2020-2033 (USD Million)
13.1. South Korea Gene Therapy Market Size and Market Share By Region (2020-2026)13.2. South Korea Gene Therapy Market Size and Market Share By Region (2027-2033)13.3. Eastern Region13.4. Western Region13.5. Southern Region13.6. Northern Region
14. Company Profile
14.1. CHA Biotech Co., Ltd.14.1.1. Company details14.1.2. Financial outlook14.1.3. Product summary14.1.4. Recent developments14.2. CORESTEMCHEMON Inc.14.2.1. Company details14.2.2. Financial outlook14.2.3. Product summary14.2.4. Recent developments14.3. Ferring International Center S.A.14.3.1. Company details14.3.2. Financial outlook14.3.3. Product summary14.3.4. Recent developments14.4. HELIXMITH Co., Ltd.14.4.1. Company details14.4.2. Financial outlook14.4.3. Product summary14.4.4. Recent developments14.5. MEDIPOST Co., Ltd.14.5.1. Company details14.5.2. Financial outlook14.5.3. Product summary14.5.4. Recent developments14.6. Novartis Korea Ltd.14.6.1. Company details14.6.2. Financial outlook14.6.3. Product summary14.6.4. Recent developments14.7. PHARMICELL Co., Ltd.14.7.1. Company details14.7.2. Financial outlook14.7.3. Product summary14.7.4. Recent developments14.8. Rznomics Inc.14.8.1. Company details14.8.2. Financial outlook14.8.3. Product summary14.8.4. Recent developments14.9. S-Biomedic14.9.1. Company details14.9.2. Financial outlook14.9.3. Product summary14.9.4. Recent developments14.10. Tego Science, Inc.14.10.1. Company details14.10.2. Financial outlook14.10.3. Product summary14.10.4. Recent developments14.11. Others
15. Conclusion
16. Reference Links
17. List of Abbreviations
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
South Korea Gene Therapy Market is projected to reach USD 15.33 million by 2033, growing at a CAGR of 16.89% during the forecast period.
South Korea Gene Therapy Market grew in Market size from 2024. The Market is expected to reach USD 15.33 million by 2033, at a CAGR of 16.89% during the forecast period.
South Korea Gene Therapy Market CAGR of 16.89% during the forecast period.
You can get the sample pages by clicking the link - Click Here
South Korea Gene Therapy Market size is USD 15.33 million from 2024 to 2033.
South Korea Gene Therapy Market is covered By Vector Type, By Method, By Gene Type, By Application and By End User
The Asia Pacific is anticipated to have the highest Market share in the South Korea Gene Therapy Market.
The Key players in the Market include Companies Covered CHA Biotech Co., Ltd., CORESTEMCHEMON Inc., Ferring International Center S.A., HELIXMITH Co., Ltd., MEDIPOST Co., Ltd., Novartis Korea Ltd., PHARMICELL Co., Ltd., Rznomics Inc., S-Biomedic, Tego Science, Inc.
The high cost of advanced diabetes drugs and the financial burden of treating diabetes remain major obstacles to market growth, despite the fact that numerous drugs have been approved for the condition and that governments and industry players are launching numerous initiatives.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
